Skip to main content
Premium Trial:

Request an Annual Quote

Regeneron Appoints Bioinformatics VP and New Chief Scientist

Premium

TARRYTOWN, NY--Regeneron Pharmaceuticals here has named David Valenzuela to the position of vice-president of genomics and bioinformatics. He was previously Regeneron's senior director for genomics and bioinformatics. In addition, the company added the title of chief scientific officer to the position of George Yancopoulos, who remains the company's senior vice-president of research.

Commenting on Valenzuela's promotion, Yancopoulos noted that the bioinformatics executive "is responsible for the identification and cloning of novel genes that serve as targets for drug screens." Yancopoulos continued, "David has made many key discoveries for Regeneron in the last four years, and we believe that in his new position David will continue to make important contributions to the company's drug discovery
programs."

Regeneron focuses on applying molecular and cell biology to the task of drug discovery.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.